The GRAPPA working group has now set out a program of research to update the core set with the aim of seeking endorsement at OMERACT 2016.
Introduction
The psoriatic arthritis (PsA) core set for outcome measures to be used in randomized controlled trials (RCTs) and longitudinal observational studies was endorsed at Outcome Measures in Rheumatology (OMERACT) 8 in Malta. 1 Considerable work within the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been undertaken over the last eight years to develop appropriate individual and composite responder indices to capture disease activity. 2, 3 At the OMERACT 10 meeting in 2012 it became clear that much of this work had been undertaken with little or no incorporation of the patient perspective. Incorporation of the patient perspective through meaningful, ongoing inclusion of patient research partners throughout the outcome measure development and domain selection process has acknowledged benefits.
The role of patients in outcome research is embedded at the heart of the OMERACT process. 4, 5 Prior examples of the benefits of this approach include the ability to determine the minimum clinically important differences (MCID) in patient reported outcomes, development of definitions of remission and flare and inclusion of fatigue and participation to the "core set" in rheumatoid Outcome Measures for Psoriatic Arthritis (PIOMPSA) initiative, 9 the Psoriatic Arthritis Impact of Disease (PsAID) study 10 and the progress made towards development of composite disease activity measures. 2 The presentations were followed by discussion in breakout groups on the need to update the PsA core set and what revisions should be considered. Results for the breakout group were presented at the plenary followed by voting (report in press).
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Review of the patient involvement initiative-PIOMPSA
The PIOMPSA effort was initiated in 2012 to improve incorporation of the patient perspective in
PsA outcomes research within GRAPPA. The first meeting in Dublin, Ireland included equal numbers of rheumatologists and patient research partners and efforts have been made to preserve this balance to give patient research partners an equal voice at the proceedings. 9 The PIOMPSA group discussed the relative lack of patient input in the development of the PsA core-set and outcome measure development and undertook a systematic literature review to define levels of patient involvement thus far together with a roadmap to enhance integration of patient perspectives in future research in PsA. The group identified a potential need to revise the existing PsA core set. This was primarily to ensure incorporation of patient involvement in the domain selection and prioritisation but additionally to incorporate the considerable research progress from 2006 onward which could inform revision of the domains constructs including;
 The 68/66 (tender/swollen) joint count having been identified as the optimal joint count for PsA assessment in clinical trials.
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 Tools to assess fatigue, enthesitis, dactylitis and the measurement of axial disease haing been developed and tested. 13, 14, 15  The Psoriasis Activity and Severity Index (PASI) having been shown to be reliable when performed by rheumatologists or dermatologists. 16 Updating the core set in light of these research findings would allow patient representation and an opportunity for movement or incorporation of domains important to patients such as fatigue, dactylitis and participation (work/ leisure activities) that were not previously included. Feedback from the breakout groups identified a number of themes. There was general agreement that there was a need to revise the PsA core set and this would present opportunities to improve the existing core set. Within the 'core area' of 'pathophysiology' there was considered to be an opportunity to amend existing redundancy. An umbrella term such as 'inflammatory musculoskeletal disease' for arthritis, enthesitis, dactylitis and axial disease could be considered.
'Psoriasis activity' may be considered as an encompassing term for skin and nail disease and 'biomarkers' for acute phase reactants. 'Life impact' concepts emerging from the breakout discussions included a strong message to retain pain, health related quality of life (HRQOL), function and patient global in the core set while adding fatigue which attendees noted had also been ranked highly in the PsAID study. 10 There was debate regarding the potential overlap of domains captured in the patient global measure as well as fatigue. There was recognition of the increasing evidence that it is legitimate to move items like dactylitis 19 , fatigue 20 and enthesitis 21 from former positions in the second circle to higher prioritization in the inner circle, especially as tools had been developed and tested since the initial core set creation to evaluate these.
The proposal to revise the PsA core set was strongly endorsed with a 100% vote by the OMERACT workshop participants and was notably the first time a unanimous vote had been achieved within OMERACT. The PsA core set will therefore be the first to undergo revision using the OMERACT Filter 2.0. Consensus was also achieved on retaining the patient global within the core set (endorsed with 70% vote) as well as adding fatigue (endorsed with 72% vote).
Conclusion
At the OMERACT 12 PsA workshop there was unanimous endorsement for the need to update the PsA core set. The results of the OMERACT breakout group discussions highlighted opportunities to involve patients as well as add, move or merge existing domains to improve existing redundancy. Work over the next two years will focus on the revision of the PsA core set according to the filter 2.0 with the aim of seeking endorsement at OMERACT 13 in 2016.
